Tucatinib/Tucatinib Dosage Detailed Guide

Tucatinib is a drug that targets HER2-positive breast cancer and is often used in combination with other drugs, especially for breast cancer patients with HER2 overexpression or gene amplification. The drug's therapeutic indications include patients with advanced or metastatic HER2-positive breast cancer and colorectal cancer, especially in patients with brain metastases. Tucatinib can significantly improve the therapeutic effect when combined with trastuzumab and capecitabine.

The recommended dosage of tucatinib is 300 mg orally twice daily. Patients should follow the treatment regimen and continue taking tucatinib until disease progression or unacceptable toxicity. Tucatinib can be used in combination with trastuzumab and capecitabine. In combination therapy, the recommended dose of capecitabine is 1000 mg/m² taken orally twice daily within 30 minutes after a meal. This can aid the absorption of the medication and enhance the therapeutic effect.

When taking tucatinib, patients need to pay attention to some medication details. First, tucatinib should be swallowed whole and avoid chewing, crushing, or splitting the tablet. The medication should be taken at the prescribed time interval of approximately 12 hours, ensuring that the medication is taken at the same time every day. Tucatinib can be taken before or after meals, and patients should ensure consistency between each dose and meal time. If the patient vomits or misses a dose of medication, he or she should continue taking the medication at the next dose and do not take the missed dose again.

In addition, the combined use of tucatinib with other drugs may cause some side effects, including diarrhea and abnormal liver function. Patients should conduct regular health examinations, especially liver function tests, during the course of taking it, and report discomfort symptoms in a timely manner so that doctors can make corresponding adjustments.

Reference materials:https://www.tukysa.com/